Every fact on this site carries an evidence grade — strong, moderate, limited or mixed — and a link to the research. Hype and fear both fail here.
CB1 receptors are sparse in the brainstem centers controlling breathing — unlike opioid receptors — which is why THC does not stop respiration even at extreme doses. The real acute dangers are psychiatric (panic, psychosis), cardiac stress in vulnerable people, and injury while impaired — especially children and edibles.
Safety & Risk STRONG EVIDENCECBD does not meaningfully activate CB1 receptors and produces no intoxication at normal doses. WHO's Expert Committee on Drug Dependence concluded CBD shows no abuse or dependence potential. "Cannabis without the high" is, for CBD alone, accurate.
CBD MODERATE EVIDENCEChemical analyses repeatedly find that commercial indica/sativa labels poorly predict cannabinoid and terpene content — the actual drivers of effects. Researchers increasingly argue for chemovar (chemical variety) classification instead of folklore taxonomy.
Terpenes & Entourage STRONG EVIDENCEEaten THC passes the liver first, where it converts to 11-hydroxy-THC — a metabolite that crosses the blood-brain barrier more efficiently and is more potent per milligram. This is pharmacology, not imagination, and why the same milligrams hit harder eaten than smoked.
THC STRONG EVIDENCEThe multi-site EU-GEI study (Lancet Psychiatry, 2019) found daily users of high-potency cannabis (>10% THC) had ~5× the odds of a psychotic disorder, with population-level impact measurable in cities like Amsterdam and London. Association is firmly established; individual susceptibility varies — family history of psychosis is the key red flag.
Safety & Risk MIXED / UNSETTLEDThe idea that cannabinoids and terpenes work better together has mechanistic support (e.g., caryophyllene at CB2) and wide anecdotal backing, but controlled human trials showing terpene combinations changing THC's effects are essentially absent. Treat it as a hypothesis, not a law.
Terpenes & EntourageRaphael Mechoulam's team in Israel isolated and synthesized Δ9-THC in 1964 — and CBD a year earlier. Despite cannabis being used for millennia, its chemistry is a modern discovery: younger than the Beatles.
Read the full fact + sources →Sixty-two facts, four evidence grades. Can you tell what the research actually supports?
Sleep, chronic pain, anxiety — what the research actually supports, graded claim by claim, with community reports kept visibly separate from the evidence.
Humans produce endocannabinoids — anandamide (named from the Sanskrit "ananda", bliss) and 2-AG — which activate the same receptors as plant THC. The system was discovered because THC worked, not the other way around: researchers found the receptor first (1988), then asked why it existed.
The Endocannabinoid System STRONG EVIDENCECB1 receptors are expressed at densities rivaling glutamate and GABA receptors across the cortex, hippocampus, basal ganglia and cerebellum. Their density in movement and memory regions explains both the therapeutic reach of cannabinoids and their side-effect profile.
The Endocannabinoid System STRONG EVIDENCEThe ECS is a homeostatic signaling system: it tunes hunger, pain signaling, stress response, sleep and memory consolidation. It works "on demand" — synthesized when needed, broken down quickly by enzymes (FAAH, MAGL). This is why cannabis touches so many functions at once.
The Endocannabinoid System STRONG EVIDENCEWhile CB1 dominates the brain, CB2 receptors concentrate in immune cells and peripheral tissues, modulating inflammation. CB2 is the main reason researchers believe cannabinoids could have anti-inflammatory effects without a high.
The Endocannabinoid System STRONG EVIDENCERaphael Mechoulam's team in Israel isolated and synthesized Δ9-THC in 1964 — and CBD a year earlier. Despite cannabis being used for millennia, its chemistry is a modern discovery: younger than the Beatles.
THC STRONG EVIDENCETHC partially activates CB1 receptors rather than fully switching them on. This partial activity is one reason cannabis has a wide safety margin compared to full-agonist synthetic cannabinoids ("spice"), which can be lethal — a critical distinction often lost in public debate.
THC STRONG EVIDENCEUS potency-monitoring data shows average THC in seized cannabis rising from ~2% in the 1970s–80s to well above 12–15% in recent years, with concentrates reaching 60–90%. "Cannabis today" and "cannabis in the studies from 1985" are not the same exposure.
THC STRONG EVIDENCEEaten THC passes the liver first, where it converts to 11-hydroxy-THC — a metabolite that crosses the blood-brain barrier more efficiently and is more potent per milligram. This is pharmacology, not imagination, and why the same milligrams hit harder eaten than smoked.
THC STRONG EVIDENCETHC metabolites are fat-soluble and linger for days (occasional use) to weeks (daily use) in urine. Roadside and workplace tests detect exposure, not impairment — one of the hardest unsolved problems in cannabis policy.
Consumption & Dosing STRONG EVIDENCECBD does not meaningfully activate CB1 receptors and produces no intoxication at normal doses. WHO's Expert Committee on Drug Dependence concluded CBD shows no abuse or dependence potential. "Cannabis without the high" is, for CBD alone, accurate.
CBD STRONG EVIDENCEPurified CBD (Epidiolex) is FDA- and EMA-approved for Dravet syndrome, Lennox-Gastaut syndrome and TSC-related seizures, cutting seizure frequency in randomized controlled trials. This is the gold standard of cannabinoid evidence: real RCTs, real approval.
CBD STRONG EVIDENCEA landmark JAMA study testing 84 online CBD products found only ~31% accurately labeled; many under-delivered CBD, and 21% contained unlabeled THC. Regulated markets with lab testing largely fix this — unregulated ones do not.
CBD STRONG EVIDENCECBD inhibits CYP450 enzymes (notably CYP3A4 and CYP2C19) that metabolize many drugs: blood thinners, anti-epileptics, some antidepressants. If a medication carries a grapefruit warning, treat CBD the same way and ask a pharmacist.
CBD LIMITED EVIDENCESmall human trials show CBD reducing experimentally induced anxiety (e.g., simulated public speaking), but large definitive trials are missing, and effective doses in studies (300–600mg) dwarf most retail products (10–25mg). The molecule is interesting; the average gummy is underdosed.
CBD STRONG EVIDENCEMyrcene is in mangoes and hops, limonene in citrus peel, pinene in pine, linalool in lavender. Cannabis is remarkable for combining dozens of them in one flower — not for owning them. This is why strain aromas map so well onto other plants.
Terpenes & Entourage MIXED / UNSETTLEDThe idea that cannabinoids and terpenes work better together has mechanistic support (e.g., caryophyllene at CB2) and wide anecdotal backing, but controlled human trials showing terpene combinations changing THC's effects are essentially absent. Treat it as a hypothesis, not a law.
Terpenes & Entourage STRONG EVIDENCEThe peppery terpene β-caryophyllene — also in black pepper and cloves — directly activates CB2 receptors. It is the best-documented case of a terpene acting like a cannabinoid, demonstrated by Gertsch et al. in 2008.
Terpenes & Entourage MODERATE EVIDENCEChemical analyses repeatedly find that commercial indica/sativa labels poorly predict cannabinoid and terpene content — the actual drivers of effects. Researchers increasingly argue for chemovar (chemical variety) classification instead of folklore taxonomy.
Terpenes & Entourage STRONG EVIDENCEPeak effects from edibles arrive far later than smoking (minutes). The classic bad experience is re-dosing at minute 45 because "nothing happened" — then both doses land together. The single most protective rule with edibles is: wait two full hours before taking more.
Consumption & Dosing MODERATE EVIDENCEVaporizers heat cannabis below combustion, and studies show drastically reduced carbon monoxide and tar byproducts versus smoking, with similar THC delivery. "Reduced harm" is accurate; "harmless" is not — long-term data is thin, and vape liquids are a separate, riskier category.
Consumption & Dosing STRONG EVIDENCEStudies sealing non-smokers in small unventilated chambers with heavy smoke produced detectable THC metabolites and mild effects. In ventilated real-world conditions, positives were rare and below standard testing thresholds. The "contact high" is real but requires genuinely extreme exposure.
Consumption & Dosing STRONG EVIDENCEControlled on-road and simulator studies show THC worsens lane weaving, reaction time and divided attention, roughly doubling crash risk at typical recreational doses. Combining with alcohol multiplies impairment well beyond either alone.
Brain, Mind & Driving STRONG EVIDENCEStudies tracking performance show measurable impairment persisting after subjective effects fade — especially with edibles, where performance deficits can extend 6–8+ hours. Feeling fine is not a reliable test of being fine.
Brain, Mind & Driving MODERATE EVIDENCELongitudinal studies associate heavy teen use with reduced memory, attention and IQ trajectories, with some effects persisting after stopping. Whether cannabis causes this or correlates with other factors is contested — but the developing brain (to ~25) is the agreed window of caution.
Brain, Mind & Driving MODERATE EVIDENCETHC reliably impairs forming new short-term memories while high (the CB1-dense hippocampus at work). In adult occasional users, studies generally find function returns after abstinence — heavy long-term use shows subtler, more persistent patterns.
Brain, Mind & Driving STRONG EVIDENCECannabis can produce a clinically defined dependence: cravings, failed cut-downs, use despite harm, and a recognized withdrawal syndrome (irritability, insomnia, appetite loss). Risk rises steeply with daily use and early initiation. "Non-addictive" is marketing, not science.
Safety & Risk STRONG EVIDENCESome long-term heavy users develop CHS — cyclic severe vomiting that, paradoxically, is relieved by hot showers and resolves only with cannabis cessation. It is frequently misdiagnosed for years. If this sounds like you or a patient, the literature is now clear.
Safety & Risk STRONG EVIDENCEThe multi-site EU-GEI study (Lancet Psychiatry, 2019) found daily users of high-potency cannabis (>10% THC) had ~5× the odds of a psychotic disorder, with population-level impact measurable in cities like Amsterdam and London. Association is firmly established; individual susceptibility varies — family history of psychosis is the key red flag.
Safety & Risk MIXED / UNSETTLEDCannabis smoke shares many carcinogens with tobacco smoke, yet large epidemiological studies have not produced the clear lung cancer signal seen with tobacco — possibly due to exposure patterns, anti-inflammatory effects, or study limits. Chronic bronchitis risk, however, is well documented. "Unclear" is not "safe."
Safety & Risk STRONG EVIDENCECB1 receptors are sparse in the brainstem centers controlling breathing — unlike opioid receptors — which is why THC does not stop respiration even at extreme doses. The real acute dangers are psychiatric (panic, psychosis), cardiac stress in vulnerable people, and injury while impaired — especially children and edibles.
Safety & Risk STRONG EVIDENCEACOG and pediatric associations recommend against use: THC crosses the placenta and concentrates in breast milk, and studies link prenatal exposure to lower birth weight and attention effects in children. THC stored in body fat can persist in milk for weeks.
Safety & Risk STRONG EVIDENCEThe landmark 2017 National Academies report — the most rigorous evidence review to date — found substantial evidence for only three indications: chronic pain in adults, chemotherapy-induced nausea (oral cannabinoids), and MS-related spasticity. Nearly everything else sits at "limited" or "insufficient."
Medical Evidence STRONG EVIDENCEDronabinol and nabilone (synthetic THC) are approved for chemo nausea and AIDS wasting; nabiximols (THC+CBD spray) is approved for MS spasticity in 25+ countries; Epidiolex (CBD) for severe epilepsy. The medical channel exists and works — it is simply narrower than the dispensary menu suggests.
Medical Evidence STRONG EVIDENCECannabinoids kill cancer cells in petri dishes and mice — as do thousands of compounds that never become medicines. No controlled human trial has shown cannabis treating cancer. It genuinely helps with chemo nausea and appetite; abandoning oncology treatment for cannabis has cost lives.
Medical Evidence MIXED / UNSETTLEDSome state-level studies found fewer opioid prescriptions and overdoses after legalization; later re-analyses with more states and years found the effect reversed or vanished. Individual patients report real substitution benefits; population evidence is unstable. An open, important question.
Medical Evidence MODERATE EVIDENCETHC does reduce intraocular pressure, but only for 3–4 hours, requiring constant intoxicating doses to protect the optic nerve. Ophthalmology societies explicitly do not recommend it. A real effect, a poor medicine — the classic case of mechanism ≠ treatment.
Medical Evidence MODERATE EVIDENCEA widely shared claim that gastric acid converts CBD to psychoactive THC comes from simulated lab fluid, not human bodies. Human studies measuring THC and metabolites after oral CBD find no meaningful conversion. Epidiolex trials at high doses confirm: patients do not get high.
Medical Evidence MODERATE EVIDENCEPeople carry different versions of FAAH, the enzyme that breaks down anandamide. One common variant slows that breakdown, raising natural endocannabinoid levels — carriers show measurably different responses to THC, including lower dependence risk in several studies. Same joint, different brain.
The Endocannabinoid System MODERATE EVIDENCEFor decades the post-run euphoria was blamed on endorphins — but endorphins barely cross the blood-brain barrier. Animal and human studies point instead to anandamide surging after sustained exercise. Your ECS, the same system THC hijacks, is the body's own reward for endurance.
The Endocannabinoid System STRONG EVIDENCECB1 and CB2 receptors, plus the enzymes that make and destroy endocannabinoids, are expressed across the gastrointestinal tract, skin, liver, fat tissue and bone. The ECS is a whole-body regulatory network, which is why cannabinoid research now spans IBS, eczema, liver disease and osteoporosis.
The Endocannabinoid System STRONG EVIDENCETHC is highly lipophilic: after use it partitions into body fat and redistributes slowly back into blood. This storage-and-release cycle is why urine tests can stay positive for weeks after the last use — and why heavy users can show measurable blood THC days into abstinence.
THC MODERATE EVIDENCEDelta-8-THC is a naturally occurring isomer, roughly half to two-thirds as potent as delta-9. Plants make it in trace amounts, so commercial delta-8 is chemically converted from CBD. That conversion market grew in a regulatory gap, with little oversight of reaction byproducts — poison-control calls followed.
THC LIMITED EVIDENCETetrahydrocannabivarin (THCV) acts as a CB1 antagonist at low doses — the opposite move of THC — and early human studies explore it for appetite control and blood-sugar regulation. Effects flip at higher doses where it can activate CB1. Fascinating pharmacology, thin human data.
THC STRONG EVIDENCEOral CBD has bioavailability around 6–13%: the liver metabolizes most of it before it reaches circulation. Taking it with a fatty meal can multiply absorption several-fold. Two identical capsules can produce wildly different blood levels depending on lunch.
CBD STRONG EVIDENCEIn the Epidiolex epilepsy trials, a meaningful share of patients on high-dose CBD (10–20 mg/kg/day) showed elevated liver transaminases, especially with valproate. This is why the label requires liver monitoring — and why megadose self-experimentation is not harmless.
CBD STRONG EVIDENCEHuman studies showing CBD effects typically use 300–600 mg per day, sometimes more. Over-the-counter products commonly suggest 5–25 mg. Whatever you believe about CBD's potential, most consumer products deliver a small fraction of studied doses — expectations should scale accordingly.
CBD MIXED / UNSETTLEDMyrcene dominates the terpene profile of many cultivars and is widely blamed for sedation. Controlled human evidence for myrcene alone sedating people is essentially absent; the claim descends from animal data at high doses and industry repetition. Abundant, yes. Proven sedative in humans, no.
Terpenes & Entourage LIMITED EVIDENCEA 2024 Johns Hopkins double-blind trial gave participants THC with vaporized limonene: anxiety and paranoia ratings dropped meaningfully at higher limonene doses. One small trial is not a prescription, but it is the first controlled human evidence for an entourage-style interaction.
Terpenes & Entourage MODERATE EVIDENCETerpenes volatilize at different temperatures — myrcene and pinene low, linalool and caryophyllene higher — so the same flower delivers a different aromatic (and possibly experiential) profile at 170°C than at 210°C. The chemistry of boiling points is solid; claims of tailored effects remain ahead of the evidence.
Terpenes & Entourage STRONG EVIDENCEAdverse effects of THC — anxiety, tachycardia, dizziness, impairment — scale with dose and peak blood level, and edibles add unpredictable absorption on top. Starting at 2.5–5 mg and waiting the full onset window before redosing is how you stay on the friendly side of the curve.
Consumption & Dosing MODERATE EVIDENCECombustion destroys a share of THC, sidestream smoke carries away more, and exhalation loses the rest — classic smoking-dynamic studies estimate roughly a fifth to a third reaches the smoker. Potency on the label is not potency in the blood.
Consumption & Dosing STRONG EVIDENCEChronic cannabis use downregulates CB1 receptors, a biological basis of tolerance. PET imaging studies show cortical CB1 availability rebounding toward normal after about four weeks of abstinence. Tolerance is real — and so is its reversal.
Consumption & Dosing STRONG EVIDENCECombined use multiplies lane weaving, reaction-time and divided-attention deficits in simulator and on-road studies, and crash-risk analyses find the combination riskier than either substance by itself. "Only a little of each" is not a safe strategy.
Brain, Mind & Driving MODERATE EVIDENCEAcross cohort and case-control studies, adolescent initiation, daily use and high-potency products form a consistent risk gradient for later psychotic disorders. Whether cannabis causes the disorder or accelerates it in the vulnerable is still argued; the association itself is one of the most replicated in the field.
Brain, Mind & Driving MIXED / UNSETTLEDControlled studies show THC acutely reduces effort people choose to expend for reward. Long-term "amotivation" findings are far weaker and confounded by lifestyle and reverse causation. The honest summary: real short-term effect, unproven permanent one.
Brain, Mind & Driving STRONG EVIDENCETHC increases resting heart rate by 20–50 beats per minute in the first hour after use and can trigger ischemia in susceptible people; registry studies link the post-use hour to elevated heart-attack risk in vulnerable users. Healthy hearts tolerate it; diseased ones deserve respect.
Safety & Risk STRONG EVIDENCETesting programs repeatedly find pesticides, heavy metals, residual solvents and mold in unregulated market products, and the 2019 EVALI lung-injury outbreak was traced to vitamin E acetate in illicit vape carts — thousands hospitalized, dozens dead. Lab-tested, regulated supply is a genuine safety feature, not bureaucracy.
Safety & Risk MODERATE EVIDENCEColorado emergency-department data found edibles caused a disproportionate share of cannabis-related visits relative to their sales share — with more acute psychiatric and cardiovascular symptoms than inhaled use. The mechanism is familiar: delayed onset, impatient redosing, too much 11-hydroxy-THC.
Safety & Risk MODERATE EVIDENCEDogs have dense CB1 expression in the hindbrain, making them unusually sensitive to THC: ataxia, dribbling urine, low heart rate. Poison-control and veterinary studies show cases climbing sharply after legalization. Edibles left in bags are the classic culprit — and yes, that is what our PetFriendlyFoods app is for.
Safety & Risk STRONG EVIDENCEDronabinol (Marinol) — synthetic THC — was approved four decades ago for chemotherapy-induced nausea and AIDS-related appetite loss, later joined by nabilone. Whatever the plant's legal status, cannabinoid medicine itself is old, established pharmacology.
Medical Evidence MODERATE EVIDENCENabiximols (Sativex), a 1:1 THC:CBD oromucosal spray, is approved across Europe, Canada and elsewhere for multiple-sclerosis spasticity that resists standard treatment. Trials show real but modest responder rates — it helps a subset of patients, not everyone.
Medical Evidence MIXED / UNSETTLEDRegistries show PTSD among the top qualifying conditions, yet the first randomized controlled trial (2021) found all cannabis arms beat placebo only marginally and inconsistently, and a large veteran cohort analysis linked cannabis use to worse outcomes over time. Hopeful mechanism, unproven treatment.
Medical EvidenceCannabisScienceFacts pairs with Cannabis Vocabulary — the network's glossary of cannabinoids, terpenes and methods.
Open the glossary →